Are CV biomarker tests worthwile?; Genetics of lung cancer;

> In a study of people without known cardiovascular disease, assessing CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened. Each test costs $60 to $150, and may or may not be covered by health plans. So, given these figures--is screening worthwhile? Abstract | Article

> According to an early analysis of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, a variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer, supporting the idea that inflammation is associated with lung cancer risk. Press release | Abstract

> The first trial of scans of breast cancer tumor whole genomes as an alternative to single-gene tests aims to help doctors select the right treatment has been carried out. Press release

> Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer. Abstract

> High blood pressure during pregnancy could be a marker for lower IQ for the children. Article

And Finally… Squeezing cells to check for stiffness could differentiate between healthy, malignant and metastatic cells. Article

Suggested Articles

Testing company LumiraDx is selling its pandemic virus rapid test across the U.K. targeting individuals without any COVID-19 symptoms.

The FDA has given genomics firm Helix a wider emergency use authorization for its pandemic test.

Celltrion has nabbed a speedy preapproval for its quick pandemic virus test as it forecasts high demand.